TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1756437
Drug: Indomethacin, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 150 mg daily for 3 days
Study: 31107913
Drug: Tenofovir (TFV)
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir (TFV) IVR (8-10 mg/day)
Study: 21929562
Drug: PLC 1
Normalized name: Phospholipase C 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLC 1 g/day
Study: 21929562
Drug: PLC 2
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PLC 2 g/day
Study: 10914843
Drug: Prednisone (4.37
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (4.37 mg daily)
Study: 1428189
Drug: Loracarbef (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef (200 mg capsule twice daily or 15 mg/kg/day oral suspension in two divided doses up to a maximum of 375 mg/day)
Study: 1428189
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (250 mg capsule four times daily or 20 mg/kg/day suspension in four divided doses up to a maximum of 500 mg/day)
Study: 3880876
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of serum concentrations of estradiol, progesterone, dehydroepiandrosterone sulfate, and testosterone before and after treatment
Study: 29520956
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate solution (2%) (NP-CHX)
Study: 29520956
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate solution (2%) (P-CHX)
Study: 24901365
Drug: Dapivirine vaginal
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine vaginal ring (25 mg) used continuously for 28 days
Study: 15629415
Drug: Oxymorphone ER
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone ER (10 to 110 mg)
Study: 15629415
Drug: Oxycodone CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone CR (20 to 220 mg)
Study: 12833472
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa for the treatment of anemia
Study: 7073809
Drug: Diflorasone diacetate
Normalized name: Diflorasone Diacetate
DrugBank: Diflorasone (DB00223)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diflorasone diacetate ointment 0.05%
Study: 7073809
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate ointment 0.05%
Study: 3619423
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg intravenously
Study: 3619423
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg orally
Study: 8617581
Drug: Didemnin B
Normalized name: Dehydrodidemnin B
DrugBank: Plitidepsin (DB04977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didemnin B at 3.5 mg/m2
Study: 8617581
Drug: Didemnin B
Normalized name: Dehydrodidemnin B
DrugBank: Plitidepsin (DB04977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didemnin B at 6.3 mg/m2
Study: 2666024
Drug: Oral beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beta-carotene (50 mg/day)
Study: 987254
Drug: Fusaric acid
Normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusaric acid calcium salt (5.1 mg/Kg to 6.0 mg/Kg)
Study: 28489737
Drug: Oral use
Normalized name: ACETEST TAB (NOT FOR ORAL USE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral use of montelukast sodium
Study: 28489737
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray of mometasone furoate
Study: 28489737
Drug: Oral use
Normalized name: ACETEST TAB (NOT FOR ORAL USE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral use of montelukast sodium + nasal spray of mometasone furoate
Study: 25836732
Drug: Telepractice delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telepractice delivery of flow phonation voice therapy exercises
Study: 25836732
Drug: In-person delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person delivery of flow phonation voice therapy exercises
Study: 19482892
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection guided by electrical stimulation plus physiotherapy
Study: 19482892
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection guided by palpation plus physiotherapy
Study: 12601540
Drug: No salvage
Approvals — FDA: no, EMA: no, PMDA: no
Description: No salvage therapy (Control)
Study: 11938859
Drug: Lumbricus solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbricus solution applied to wound surface after hemorrhoidectomy
Study: 11938859
Drug: Lumbricus solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbricus solution
Study: 11938859
Drug: Lumbricus preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbricus preparation
Study: 27431239
Drug: Multimedia intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimedia intervention delivered daily from Day 1 to Day 5 via iPad™, comprising information on the goals of care for each day following surgery.
Study: 12865917
Drug: Stopped hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stopped hormone replacement therapy (HRT)
Study: 1857480
Drug: Desferrioxamine (DFO)
Normalized name: DFO
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desferrioxamine (DFO) at a dose of 20-30 mg/kg
Study: 1857480
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (r‐HuEPO) at a dose of 40 units/kg/dialysis i.v.
Study: 31250239
Drug: Treatment-as-usual (n=44)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (n=44)
Study: 29905904
Drug: Beta-alanine (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (6.4 g day-1)
Study: 24931055
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to daily caloric intake goals
Study: 19994686
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (oral Diclofenac sodium and intramuscular Methotrexate)
Study: 14731164
Drug: Ritonavir 200
Normalized name: lopinavir-ritonavir 200 mg-50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 200 mg bid
Study: 14731164
Drug: Lopinavir 400
Normalized name: LOPINAVIR 400MG/RITONAVIR 100MG/5ML SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir 400 mg bid added on day 15
Study: 7963907
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg rifampin (RMP)
Study: 7963907
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg rifampin (RMP)
Study: 7963907
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of rifampin (RMP)
Study: 7963907
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of rifampin (RMP)
Study: 3115136
Drug: Ro 15-1788
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15-1788 (1 ml = 0.1 mg active drug)
Study: 26823128
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kg) in CC trial
Study: 26823128
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kg) in PC trial
Study: 20306851
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (control group, n = 66)
Study: 15749459
Drug: 10‐mg amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg amlodipine tablet formulation
Study: 12739704
Drug: Loperamide (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (8 mg + 4 mg + 4 mg, administered 12 h and 2 h before, and 7 h after the start of the recording)
Study: 8703558
Drug: TA-0910 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA-0910 (10 mg or 20 mg daily)
Study: 30729947
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CNT) with no antibacterial agents
Study: 29130810
Drug: Intravenous 1.26%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 1.26% sodium bicarbonate
Study: 29130810
Drug: Intravenous 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.9% sodium chloride
Study: 30466822
Drug: Oral acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetylcysteine
Study: 22976492
Drug: ACH-1625 (monotherapy)
Normalized name: ACh
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACH-1625 (monotherapy)
Study: 20236198
Drug: Pale sulfonated
Normalized name: pale dock pollen extract
DrugBank: Rumex altissimus pollen (DB10901)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pale sulfonated shale oil (PSSO) cream 4%
Study: 17662293
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of red wine (4.0+/‐0.4 dl)
Study: 17662293
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of red wine (8.1+/‐0.9 dl)
Study: 17662293
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of red wine
Study: 15933926
Drug: 4 l
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 l polyethylene glycol (PEG)
Study: 15933926
Drug: 2 l
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 l PEG plus 10 mg Bisacodyl
Study: 15933926
Drug: 90 ml
Normalized name: 190 ML Infugem 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 ml sodium phosphate
Study: 8908380
Drug: GLP-1 treatment
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 treatment with regular insulin from day 8 to 12 and GLP-1 only at meals on days 13 and 14
Study: 23764734
Drug: GLP-1 treatment
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 treatment
Study: 8908380
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (insulin only)
Study: 6419594
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg auranofin daily
Study: 6419594
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg auranofin daily
Study: 6419594
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg auranofin daily
Study: 6419594
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg auranofin daily
Study: 28912054
Drug: Pharmacist interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist interventions including patient, laboratory, and individualized CV risk assessments; treatment recommendations; prescription adaptations; and regular monthly follow-up for 3 months.
Study: 27648286
Drug: Technosphere inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technosphere inhaled insulin (TI) during URTI
Study: 26718805
Drug: Technosphere inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technosphere inhaled insulin (TI) during meal challenges
Study: 18537977
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of anti-PMS1 antibody
Study: 18537977
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no HLA-DR15, no PNH-type cells, no anti-PMS1 antibody)
Study: 17767017
Drug: Leukocyte therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte therapy (immunization by isolated lymphocytes from husbands, 50 to 100 million washed and resuspended mononuclear cells injected by I.V., S.C., and I.D. route, repeated immunization if needed)
Study: 17767017
Drug: Leukocyte therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte therapy in primary aborters
Study: 17767017
Drug: Leukocyte therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte therapy in secondary aborters
Study: 10894866
Drug: Standard-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose regimen (arm A): doxorubicin (50 mg/m² on day 1) and ifosfamide (5 g/m² on day 1)
Study: 10894866
Drug: Intensified regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified regimen (arm B): doxorubicin (75 mg/m² on day 1), ifosfamide (5 g/m² on day 1), and rhGM-CSF (250 microgram/m² on days 3 to 16)
Study: 6139040
Drug: dexchlorpheniramine maleate
Normalized name: Dexchlorpheniramine Maleate
DrugBank: Dexchlorpheniramine (DB13679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dexchlorpheniramine maleate sustained release tablets (6 mg b.d.)
Study: 6139040
Drug: budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide nasal spray (200 micrograms b.d.)
Study: 27777180
Drug: Daily inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily inhaled corticosteroids (ICSs)
Study: 27777180
Drug: Daily leukotriene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily leukotriene receptor antagonists
Study: 27777180
Drug: As-needed ICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed ICS treatment coadministered with albuterol
Study: 19021920
Drug: Organically produced
Normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organically produced carrots (200 g/d; 2 weeks)
Study: 19021920
Drug: Conventionally produced
Normalized name: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally produced carrots (200 g/d; 2 weeks)
Study: 9817267
Drug: Epirubicin (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (cumulative doses greater than 950 mg/m2)
Study: 25955227
Drug: Levothyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (L-T4) treatment for 6 months
Study: 17685736
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER (75 mg/day to 300 mg/day)
Study: 14717655
Drug: Hypoglycaemia (2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemia (2.7 mmol/l)
Study: 14717655
Drug: Normoglycaemia (4.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoglycaemia (4.7 mmol/l)
Study: 11591895
Drug: Once-daily administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily administration of gentamicin (6.5 mg/kg starting dose, adjusted to 7.3 mg/kg per day)
Study: 11591895
Drug: Multiple-daily administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-daily administration of gentamicin (6.8 mg/kg per day)
Study: 7992810
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of Tc-99m pertechnetate at acupuncture point K-3 (Taixi)
Study: 7992810
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of Tc-99m pertechnetate at other acupuncture points (APs)
Study: 7992810
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of Tc-99m pertechnetate at non-acupuncture points (NAPs)
Study: 2659954
Drug: Org OD
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org OD 14 (new steroid drug taken orally)
Study: 30283029
Drug: Ketamine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1.0 mg/kg
Study: 26202811
Drug: Alteplase plus
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase plus oral fingolimod 0.5 mg daily for 3 consecutive days
Study: 22841937
Drug: RapidArc (Volumetric-modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: RapidArc (Volumetric-modulated arc therapy)
Study: 22028623
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment with gemcitabine and bevacizumab
Study: 12382151
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) 2.0 g/kg given over 24 or 48 hours
Study: 9651568
Drug: Acipimox (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (3 X 250 mg daily for 12 weeks)
Study: 9651568
Drug: Acipimox (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (3 X 250 mg daily for 12 weeks) in a subgroup of 8 patients with baseline TG > 4 mmol L-1
Study: 2539830
Drug: Cod liver
Normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod liver oil (CLO) supplementation (25 ml daily for 8 weeks)
Study: 368817
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of chlorpromazine
Study: 368817
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of amitriptyline
Study: 368817
Drug: 18 mg
Normalized name: niacin 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg of dextroamphetamine sulfate
Study: 28439716
Drug: First-generation antipsychotic
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotic drugs
Study: 23102531
Drug: Aggressive fever
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive fever control strategy (acetaminophen, physical cooling); acetaminophen dose: 2275 mg
Study: 23102531
Drug: Permissive fever
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permissive fever control strategy; acetaminophen dose: 0 mg
Study: 22132651
Drug: Combined VHA/VHB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined VHA/VHB vaccine (HAB group)
Study: 22132651
Drug: Concomitant VHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant VHA and VHB vaccines (ENG+HAV group)
Study: 22132651
Drug: Concomitant VHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant VHA and VHB vaccines (HBVX+VAQ group)
Study: 19368782
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated subunit influenza vaccine Influvac®
Study: 16344276
Drug: Booklet about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booklet about chemotherapy (n = 72)
Study: 9032742
Drug: 17 beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta‐estradiol 2 mg plus norethisterone acetate 1 mg
Study: 8060436
Drug: Albuterol powder
Normalized name: albuterol Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol powder 200 micrograms inhaled every 4 hours (Group I)
Study: 8060436
Drug: Albuterol nebulized
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol nebulized solution 2.5 mg inhaled every 4 hours (Group II)
Study: 30859944
Drug: Brexpiprazole (flexible-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole (flexible-dose 1-4mg/day)
Study: 28449955
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral naltrexone (7-day washout period)
Study: 26284539
Drug: Nonresponders (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresponders (no treatment intervention specified)
Study: 26284539
Drug: IL28B CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL28B CC genotype
Study: 25098489
Drug: Synbiotic [Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic [Lactobacillus acidophilus NCFM (10(9) CFU) and cellobiose (5 g)]
Study: 23134997
Drug: Lidocaine diluted
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine diluted with normal saline (3 mL of 1% lidocaine + epinephrine in 30 mL of bacteriostatic 0.9% sodium chloride in a 1:10 ratio)
Study: 23134997
Drug: Buffered lidocaine
Normalized name: buffered lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered lidocaine (5 mL of 8.4% sodium bicarbonate solution and 50 mL of 1% lidocaine + epinephrine in a 1:10 ratio)
Study: 17804079
Drug: All therapies
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All therapies (short-term and long-term)
Study: 14574055
Drug: Clinical score
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical score treatment (Control)
Study: 10589358
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination therapy with hydroxychloroquine, sulfasalazine, and methotrexate (MTX)
Study: 8933780
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate, 200 micrograms once daily
Study: 1805294
Drug: Fluoxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (60 mg/day PO)
Study: 6425713
Drug: l-tryptophan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-tryptophan (40 mg/kg body weight)
Study: 31227374
Drug: Septoplasty with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Septoplasty with or without concurrent turbinate surgery